Mateon Announces the Filing of an IND with US FDA to Evaluate its Antisense Drug Candidate OT-101 in COVID-19 patients

NEXT STORY
Generex Biotechnology Publishes Response to Congressional Letter Calling for COVID-19 Challenge Studies and Alternative Solution to Accelerate Vaccine Development
PREV STORY
Theratechnologies Announces New Positive Results for two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Les neuf premiers mois de l’exercice marqués par une croissance de 1% à taux de change constants et par l’impact significatif de la pandémie de COVID-19

author_avatar
NASDAQ Market News

Seoul National University Hospital and Syapse Sign Multi-Year Renewal Agreement to Expand Access to Precision Medicine in South Korea

author_avatar
NASDAQ Market News

Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for COVID-19 Vaccine and Cancer Treatment

author_avatar
NASDAQ Market News